SAN CARLOS, Calif., Sep 11, 2006 (BUSINESS WIRE) -- Nektar Therapeutics (Nasdaq:NKTR) will be presenting at the Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference in London, on Thursday, September 21 at 11:20am (UK Time). Chris Searcy, vice president of corporate development, will be presenting the corporate overview at Merrill Lynch. John Patton, co-founder and chief scientific officer, will be presenting at the Oppenheimer Diabetes Conference in New York, on Thursday, September 21 at 11:30am ET. Rob Chess, chairman and acting president and chief executive officer, will be presenting at the UBS Investment Bank 2006 Global Life Sciences Conference in New York, on Wednesday, September 27 at 8:00am (Eastern Time).

The live presentations may be accessed on the investor relations' page at www.nektar.com and will be available for two weeks following each webcast.

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading drug delivery technologies, expertise and manufacturing capabilities. Nektar technology and know-how have enabled nine approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its drug delivery technologies and expertise to existing medicines to enhance performance, such as improving efficacy, safety and compliance.

SOURCE: Nektar Therapeutics

Nektar Therapeutics
Joyce Strand, 650-631-3138
Jennifer Ruddock, 650-631-4954

Copyright Business Wire 2006

News Provided by COMTEX